Clinical Trial Update: (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating CGT9486 vs placebo in indolent or smoldering systemic mastocytosis. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Systemic Mastocytosis
• Smoldering Systemic Mastocytosis
• Systemic Mastocytosis

Drugs mentioned

• CGT9486 (PLX9486)

Snippet

Sponsor: Cogent Biosciences, Inc. | Conditions: SSM, Mastocytosis, Indolent | Phase 2 | Status: ACTIVE_NOT_RECRUITING